Physician profile
Lynn E Iler
NPI 1356351126
$2,062.89
in general payments reported to CMS, 2019-2025
16 companies · $334 in 2025
The $334 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $574 · 2020: $180 · 2022: $283 · 2023: $578 · 2024: $113 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,025.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,025.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $485.41 | 2022-2025 | |
| Pfizer INC. | $326.73 | 2019 | |
| Incyte Corporation | $230.05 | 2022-2024 | Opzelura |
| Amgen INC. | $204.00 | 2020-2023 | Otezla |
| Galderma Laboratories, L.P. | $134.77 | 2025 | Nemluvio |
| Almirall LLC | $113.90 | 2023 | Klisyri |
| Leo Pharma INC. | $94.09 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $92.13 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $89.99 | 2019 | |
| Lilly USA, LLC | $85.55 | 2020 | |
| Janssen Biotech, INC. | $77.62 | 2022-2025 | Tremfya, Stelara, Simponi |
| Allergan, INC. | $56.34 | 2019 | |
| Dermavant Sciences, INC. | $31.71 | 2024 | Vtama |
| Genzyme Corporation | $20.36 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.46 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $7.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Iler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.